Novo Nordisk (NVO) FY25 earnings call

Novo Nordisk delivered robust FY25 performance, driven by strong GLP-1 sales and the successful launch of the Wegovy pill in the U.S. The company is sharpening its strategic focus on obesity and diabetes, supported by significant pipeline advancements. However, the outlook for 2026 anticipates sales and operating profit declines due to substantial pricing headwinds and increased competition, which the company views as an investment in future volume growth.